StoxAlkem Laboratories vs Fortis Healthcare: share price & financials comparison
NSE: ALKEM vs FORTIS · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Alkem Laboratories vs Fortis Healthcare at a glance
Alkem Laboratories (ALKEM) has a market capitalisation of ₹63,326 Cr, against ₹57,898 Cr for Fortis Healthcare (FORTIS). Over the past year Alkem Laboratories has returned -4.3%, compared with -27.3% for Fortis Healthcare. On valuation, Alkem Laboratories trades at a lower P/E of 29.4 versus 55.8. Alkem Laboratories earns a higher return on equity (15.6% vs 9.9%). Alkem Laboratories comes out ahead on size, valuation, profitability, financial health and technicals. Fortis Healthcare comes out ahead on growth. Across the scored metrics below, Alkem Laboratories leads on 11 and Fortis Healthcare on 7. On StoxGud's 10-point checklist, Alkem Laboratories scores 6/10 and Fortis Healthcare scores 4/10.
| Metric | Alkem Laboratories | Fortis Healthcare |
|---|---|---|
| Size | ||
| Market cap | ₹63,326 Cr | ₹57,898 Cr |
| Revenue (latest FY) | ₹14,712 Cr | ₹9,128 Cr |
| Net profit (latest FY) | ₹2,302 Cr | ₹1,042 Cr |
| Valuation | ||
| P/E | 29.4 | 55.8 |
| P/B | 4.58 | 5.53 |
| Dividend yield | 0.97% | 0.13% |
| Profitability | ||
| Return on equity | 15.6% | 9.9% |
| Net profit margin | 14.3% | 10.5% |
| Operating margin | 20.1% | 22.2% |
| Growth | ||
| Revenue growth (YoY) | +10.9% | +17.3% |
| Net profit growth (YoY) | -21.7% | -3.0% |
| Revenue CAGR (multi-year) | +9.9% | +17.8% |
| Financial health | ||
| Debt to equity | 0.12 | 0.30 |
| Momentum | ||
| 1-month return | -1.0% | -1.6% |
| 1-year return | -4.3% | -27.3% |
| 3-year CAGR | +11.5% | +32.0% |
| 5-year CAGR | +8.0% | +25.0% |
| 10-year CAGR | +13.0% | +16.3% |
| Distance from 52W high | -10.1% | -26.6% |
| Technicals | ||
| RSI (14) | 71 | 57 |
| Price vs 200-day avg | -2.4% | -14.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Alkem Laboratories | Fortis Healthcare |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✗ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 6/10 | 4/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Alkem Laboratories or Fortis Healthcare?
Alkem Laboratories has a market cap of ₹63,326 Cr and Fortis Healthcare has a market cap of ₹57,898 Cr as of 06 Nov 2026.
Which has a lower P/E, Alkem Laboratories or Fortis Healthcare?
Alkem Laboratories has the lower P/E: Alkem Laboratories trades at 29.4 and Fortis Healthcare at 55.8.
Which gave better returns in the last year, Alkem Laboratories or Fortis Healthcare?
Alkem Laboratories did better: Alkem Laboratories returned -4.3% and Fortis Healthcare returned -27.3% over one year.
Is Alkem Laboratories or Fortis Healthcare a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Alkem Laboratories scores 6/10 and Fortis Healthcare scores 4/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.